Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioCryst Pharmaceuticals, Inc. (BCRX) vs Xeris Biopharma Holdings, Inc. (XERS)

BioCryst Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. BioCryst Pharmaceuticals, Inc. is the larger, with a market value of $2.2B against $1.6B — 1.3× the size. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 68.7% against 36.3%. Xeris Biopharma Holdings, Inc. has the higher net margin (−5.12% vs −40.9%) and the higher return on invested capital (18.9% vs −610.6%). Across the 18 metrics below, BioCryst Pharmaceuticals, Inc. leads on 11 and Xeris Biopharma Holdings, Inc. on 7.

Valuation

Metric BCRX XERS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.32 4.69 2.25
P/B n/m n/m 1.90
Price to free cash flow 5.85 28.25 16.54
EV/EBITDA n/m 32.20 12.29
EV/Sales 2.84 5.08 2.56
Earnings yield (16.76%) (1.06%) (2.99%)
Free cash flow yield 17.11% 3.54% 0.00%

Profitability

Metric BCRX XERS Drug Manufacturers Specialty & Generic median
Gross margin 97.78% 86.58% 53.94%
Operating margin (33.29%) 10.91% 0.00%
Net margin (40.90%) (5.12%) 0.00%
Free cash flow margin 39.75% 16.60% 0.00%
Return on equity 87.84% 118.22% (0.40%)
Return on assets (75.79%) (4.60%) (3.32%)
Return on invested capital (610.55%) 18.88% 0.00%

Growth

Metric BCRX XERS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 68.72% 36.33% 10.01%
EPS growth (last fiscal year) 381.40% 100.86% —
Revenue growth, 5-year CAGR 117.89% 70.20% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCRX XERS Drug Manufacturers Specialty & Generic median
Debt to equity (1.85) (25.95) 0.05
Current ratio 2.32 1.45 2.31
Net debt to EBITDA 0.61 2.67 0.85

Dividend

Metric BCRX XERS Drug Manufacturers Specialty & Generic median
Dividend yield 3.71% — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric BCRX XERS Drug Manufacturers Specialty & Generic median
Market cap 2.18b 1.63b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack